HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C
Summary: Treatment-Naive Genotype 1a With Compensated Cirrhosis
Recommended and alternative regimens listed by pangenotypic, evidence level and alphabetically for:
Treatment-Naive Genotype 1a Patients With Compensated Cirrhosisa
RECOMMENDED
DURATION
RATING
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)
12 weeks
I, A
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b
8 weeks
I, B
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)
12 weeks
I, A
ALTERNATIVE
DURATION
RATING
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg)
12 weeks
I, A
a For decompensated cirrhosis, please refer to the appropriate section. b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.
